GoodRx Rises Despite Weak Earnings, Forecast By

© Reuters.

By Christiana Sciaudone — GoodRx rose 6% despite reporting earnings and guidance that missed the mark, if by a small margin.

Earnings per share of 7 cents missed expectations by a hair while sales of $160.4 million fell just short of the $160.5 million analysts had forecast, according to data compiled by Revenue for the year was estimated at $740 million to $760 million, below the consensus of $784.4 million, according to StreetInsider. On the slightly more positive side, sales for the second quarter are expected at $172 million to $176 million versus the forecast of $172.4 million. 

Shares of GoodRx have slipped more than 40% since the company went public in September. The threat of Amazon (NASDAQ:) has since reared its giant head in the world of healthcare, sending shivers down the spines of investors who fear that GoodRx could take a major hit from the rivalry.

Analysts from RBC Capital to Barclays (LON:) dropped the company’s price target following the first quarter results.

On Thursday, Bloomberg, citing people familiar with the situation, reported that GoodRx bought discount drug company RxSaver from Vericast Corp., controlled by billionaire Ronald Perelman. 


Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button